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Abstract
Background: Iloprost has been suggested to possess anti-inflammatory and immunomodulating actions and it is
widely use as a vasodilatator in systemic sclerosis (SSc). In this study we evaluate the effect of iloprost on immune
response in SSc patients. To this extend we enrolled 15 women affected by SSc and infused iloprost for 5 days.
The effect of iloprost on T cells and monocytes was measured by flow cytometry, Real time PCR and measuring
cytokines production in vivo and in vitro by ELISA.
Results: Our results demonstrate that Iloprost reduces T cell and TNF alpha production both in vivo and in vitro. It
reduces T regulatory cells number, but increases their activity after immune stimulation. It increases serum IL-2 and
this increase persists 28 days after the last infusion, also RANKL was increased both in vivo and in vitro. We
observed no effect on IFN gamma production.
Conclusions: These results suggest that iloprost has anti-inflammatory and immunomodulating effects, reducing
TNF alpha production by T cells and the number of T regulatory cells and increasing IL-2 and RANKL.
Background
Systemic sclerosis (SSc) is a disease whose extremely
complex, multifaceted pathogenesis cannot be referred
to a single hypothesis, even if fundamental abnormalities
in three or more types of cells are involved: fibroblasts,
endothelial cells and cells of the immune system, namely
T and B lymphocytes [1]. Mononuclear cells (mainly T
cells) in the SSc skin infiltrates produce cytokines and
growth factors responsible for the onset and progression
of fibrosis and microvascular damage. The role of this
immune dysfunction is not fully clear. Altered cellular
immunity is revealed by aberrant T cell biology in both
the skin, where the lesions display various features con-
sistent with T cell activation [2-4], and the circulation,
where CD4+ T cells are increased [2,5], and natural
killer T cells are decreased [6]. Lastly, circulating T cells
from SSc patients produce more inflammatory media-
tors compared to those from healthy controls [7,8].
An important role as controllers of self-reactivity [9]
has recently been defined for T regulatory cells (Treg) in
autoimmune disease. These cells are defined as CD4+/
CD25bright/FoxP3+. In SSc, both an increase in their abso-
lute number and a reduction of their function have been
demonstrated [10].
A high proportion of SSc patients suffer from
Raynaud’s phenomenon. This is a vasospastic disorder
that causes discoloration of the fingers, toes and occa-
sionally other extremities, and its persistence may result
in acral ulcer and significantly reduce the quality of life
[11]. Prostaglandin (PG) analogues, particularly the
PGI2 analogue iloprost, are widely used as vasodilators
to treat this disorder [12].
Patients with SSc receiving Iloprost report a reduction
in skin tightness, suggesting that this drug inhibits skin
fibrosis. It has been suggested that iloprost reduces skin
fibrosis by reducing collagen synthesis [13,14], the pro-
fibrotic cytokine connective tissue growth factor [15]
and the fibrotic response [16].
Iloprost has since been shown to possess anti-
inflammatory and immunomodulating actions, both in
vitro [17-20] and in vivo [21-24]. Of the two studies in
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humans [21,22], only Filaci et al. [22] evaluated the
effect of iloprost in SSc. Its potential in this disease is
thus an open question.
Here we demonstrate that iloprost decreases the pro-
duction of TNF a by acting on T cells, ameliorates Treg
function, and increases IL-2.
Methods
Patients
The study was approved by the “Clinical Study Review
Committee” of Turin’s “Ordine Mauriziano” Hospital,
and all the patients signed an informed consent state-
ment prior to their recruitment.
Fifteen women with SSc aged 53 ± 11 (7 in postmeno-
pause) were enrolled. None were taking corticosteroids,
estrogen, or immunosuppressants, or had previously
received iloprost. Their SSc was classified as grade I
accordng to Medsger et al. [17] and its mean duration
was 26 ± 17 months. Raynaud’s phenomenon was
always present. All the patients complained of side-
effects, but continued the infusions and reached satisfac-
tory drug levels. The mean quantity infused was 0.8577 ±
0.1722 ng/Kg/min for 6 hrs/day for 5 days. All the
patients started a second iloprost course after 28 days.
Treatment
Iloprost was infused intravenously according to the stan-
dard protocol [11] for 6 h/day for 5 consecutive days.
The target dose was 2 ng/kg/min.
Blood was drawn from an antecubital vein after an
overnight fast of 10 or more hours at baseline, after the
5-day treatment, and then after a further 28 days to
evaluate the timing of its action; 28 days were chosen
since in clinical practice another course is started at the
end of this period.
All measurements were performed from a single blood
sample at a single time point per patient.
Media, reagents, and chemicals
Cells were maintained in RPMI 1640 (Sigma-Aldrich, St
Louis MO) supplemented with 2 mM L-glutamine 10%
fetal bovine serum (FBS), benzyl penicillin (100 IU/ml)
and streptomycin (100 μg/ml), phytohemoagglutinin
(PHA: Sigma-Aldrich, St Louis MO.) was added in the
stimulated condition.
IL-2 was purchased from R&D Systems (Minneapolis,
MN, USA). Iloprost ([100 ng/ml], was kindly provided
by Italfarmaco, Italy).
Cells
Peripheral bood mononuclear cells (PBMCs) from SSc
patients were obtained with the Ficoll-Paque method
from 40 ml peripheral blood in lithium heparin at base-
line, after 5 days iloprost infusion, and at 28 days after
the last infusion. PBMC cultures were performed in tri-
plicate for each subject in 96-well plates [1 × 105 cell/
well]. For in vitro experiments PBMCs were obtained
from buffy coats (five independent experiments).
Ab
Fluorescein (FITC) conjugated anti-CD25, phycoerythrin
(PE) conjugated anti-CD69 PE-conjugated anti-TNF a
were purchased from Biolegend (San Diego, CA).
Peridinin chlorophyll protein (PeRCP) conjugated anti-
CD3 was purchased from Becton & Dickinson (Bedford,
MA).
T reg staining kit and APC-conjugated anti-CD14
were purchased from eBioscience (San Diego, CA).
Flow cytometry
For intracellular staining, brefeldin ([10 μg/mL], Sigma-
Aldrich, St. Louis, MO) was added to the cells for 1 hr.
Cells were harvested, stained with surfaces antibodies,
then permeabilized with saponin 5% (Sigma-Aldrich,
St. Louis, MO) for 20 min washed and blocked for non-
specific binding sites using normal rat serum before the
intracytoplasmic staining (TNF a and FoxP3) was per-
formed. All the experiments were performed with cells
stained with specific isotype control.
Flow cytometry was performed on a FACSCalibur flow
cytometer (Becton Dickinson, Franklin Lakes, NJ, USA).
Cytokine measurement
Serum IL-2 (Bender Med System, Vienna, Austria), total
RANKL (BioVendor, madrice, Czech Repubblic), TNF a
(DuoSet, R&D System Inc, Minneapolis, MN) and TGF
b1 (DuoSet, R&D System Inc, Minneapolis, MN) were
measured by ELISA. The levels of TNFa, free RANKL,
TGF b1 and INFg (Bender Med System, Vienna,
Austria) were also measured in the supernatants from
cultures stimulated or not with PHA.
Real time RT-PCR
Total cellular RNA was isolated using TRIzol reagent
(Ambion, Huntingdon, UK), chloroform extraction, and
subsequent isopropanol precipitation according to the
manufacturer’s protocol. 1 μg of RNA was converted up
to single-stranded cDNA by the High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Warring-
ton, UK). cDNA was stored at -20°C until use. b-Actin
was the housekeeping control. RQ-PCR analysis of
RANKL and TGFb1 was performed by the iCycler iQ™
system (Bio Rad, Hercules, CA, USA). TaqMan probes
were designed using Primer Express v2.0 software and
synthesized by Applied Biosystems (Warrington, UK).
FoxP3 expression was quantified by the Syber Green
method. The following primers were used: RANKL sense
5’-GCCTTTTGCTCATCTCACTATTAATG-3’ and
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antisense 5’-TGGTACCAAGAGGACAGACTCACTT-3’;
TGF-b sense 5’- TTTGATGTCACCGGAGTTGTG-3’
and antisense 5’- GCGAAAGCCCTCAATTTCC-3’;
FOXP3, sense 5’-CAGCTGCTCGCACAGATTACTT-3’
and antisense 5’-GGGACAGGATTGTGACATTTTGT-3’.
Statistics
The normal distribution of each parameter was deter-
mined with Kurtosis’ test: PBMC subsets, the cytokines
(except for serum IL-2, serum RANKL and TGFb in the
supernatants) and genes measured were normally distrib-
uted. Student’s paired t test was used to compare gaus-
sian variables at baseline and after iloprost (5 and 28
days). Wilcoxon’s test was used to compare non-gaussian
variables at baseline and after iloprost (5 and 28 days).
The SPSS 17.0 software package was used to process
the data with p < 0.05 as the significance cut-off.
Results
Iloprost reduces T cell and TNF a production
Involvement of iloprost in control of the immune
response and inflammation has been suggested [18-23],
though there are no data indicative of this effect in SSc.
1A illustrates the significant reduction of T cells
achieved after 5 days of lloprost, whereas monocytes are
not affected. T cells returned to the baseline level 28 days
after the last infusion. As TNF a is produced mainly by T
cells and monocytes among PBMCs and it is increased in
inflammation, we looked at the effect of iloprost on TNF
a producing cells. Figure 1B shows that TNF a produ-
cing T cells decreased after 5 days of iloprost and
returned to baseline 28 days after the last infusion,
whereas TNF a producing monocytes were not affected.
These findings could reflect diminished T cell activa-
tion, but evaluation of the early and late T cell activation
0.026 0.021
CD3+ CD14+
0
25
50
75
basal
Day 5
Day 28
Po
si
tiv
e 
ce
lls
 (%
)
A 0.046 0.006
CD3+/TNF+ CD14+/TNF+
0
25
50
75
100
Po
si
tiv
e 
ce
lls
 (%
)
B
C
0
25
50
75
Iloprost 15'
Iloprost 120'
Basal
CD
3+
 
c
e
lls
 
(%
)
Figure 1 Iloprost reduces T cells. PBMCs isolated from SSc patients at baseline and after treatment with iloprost (5 days of daily treatment, 28
days after the last infusion) were analysed by flow cytometry to evaluate T cells, monocytes, TNF a production and degree of T cell activation.
A. Graph shows the percentage of T cells (CD3+) and of monocytes (CD14+) among PBMCs. Bars represent mean and SD for all the patients, p
values were calculated by a paired Student’s t test, significant values are displayed. B. Graph shows the percentage of TNF a producing T cells
(CD3+, gated on lymphocytes) and monocytes (CD14+, gated on monocytes). Bars represent mean and SD for all the patients, p values were
calculated by a paired Student’s t test, significant values are displayed. C. In vitro challenge of PBMCs culture with iloprost for 15 and 120 min.
Graph shows the percentage of T cells (CD3+) in PBMCs. Bars represent mean and SD of five independent experiments. The reduction is not
statistically significant.
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markers CD69 and CD25 disclosed at non significant
reduction of such activation (data not shown).
To determine whether iloprost reduces T cells
directly, we incubated PBMCs from buffy coats (five
experiments) with iloprost. Figure 1C suggests that ilo-
prost might reduce the number of T cells in vitro, even
though the results are not statistically significant.
Confirmation of iloprost’s anti TNF a effect was
sought by measuring TNF a levels in supernatants from
PBMC cultures stimulated or not with PHA. As
expected, PHA increased TNF a secretion. Iloprost
reduced this response and hence the production of TNF
a (Figure 2A), whereas it had no effect on TNF a in the
unstimulated culture (Figure 2B). We found no decrease
in serum TNF a after iloprost (data not shown). This
datum points to the specific action of iloprost against T
cells and its ability to reduce TNF a production in
response to T cell stimulation.
Iloprost reduces T regs in vivo and in vitro
Since altered Treg number and activity may be impor-
tant in SSc [10], we evaluated these cells as a possible
iloprost target. We studied T cells by flow cytometry
and confirmed our data by analysing FoxP3 expression
by real time RT-PCR. Figure 3A &3B demonstrate a
reduction of Treg cells after 5 days of iloprost infusion.
TGF b1 is mainly produced by Treg cells within
PBMCs and it is a marker of their function [28,29], we
measured this cytokine in the PBMCs culture superna-
tants at baseline and after iloprost with and without
immune stimulation. The data in Figure 4A show a sig-
nificant increase in TGF b1 in the PBMCs supernatants
after stimulation with PHA following iloprost, hence
suggest that iloprost influences the response of Treg
cells to immune stimulation.
Serum TGF b 1 is not influenced by iloprost (data not
shown): this datum points to a specific action of iloprost
against T cells producing TGF b1, the Treg as TGFb1 is
produced by a variety of other cells in vivo.
Increased TGF b1 expression was also corroborated by
real time PCR experiments on PBMCs incubated with
iloprost for 15’ and 120’ in the presence or absence of
PHA (Figure 4B).
Treg cells are mainly involved in maintenance of self-
tolerance, which is disrupted in SSc as in other immune
disorders [9,10,30,31]. Our data suggest that iloprost can
enhance self tolerance and hence be useful in the treat-
ment of SSc.
Iloprost increases RANKL production
Receptor activator of nuclear factor B ligand (RANKL)
is a cytokine with pleiotropic functions deeply involved
in control of the immune system, and increased in
inflammation [24]. Among PBMCs it is mainly produced
by T cells [33]. Here we investigated the effect of iloprost
on this cytokine. Iloprost increases RANKL production
by PBMCs in cultures both after 5 days of infusion and
Figure 2 Iloprost treatment reduces TNF a production from
PBMCs after stimulus with PHA. TNF a was measured in the
culture supernatants of PBMCs from SSc patients treated with
iloprost at baseline and after treatment (5 days of daily treatment,
28 days after the last infusion), cultures were stimulated or not with
PHA which predominantly stimulates T cells. A. Graph shows the
level of TNF a supernatants 24 hrs after stimulus with PHA. Symbols
represent mean and SD for all the patients, p values were calculated
by paired Students’ T test, significant values are displayed. B. Graph
shows the level of TNF a supernatants without PHA. Symbols
represent mean and SD, for all the patients.
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Figure 3 Iloprost reduces Tregs. PBMCs isolated from SSc patients
at baseline and after treatment with iloprost (5 days of daily
treatment, 28 days since the last infusion) were analysed by flow
cytometry to evaluate Tregs (CD4+/CD25bright/FoxP3+
lymphocytes) and by real time PCR to evaluate FoxP3 expression. A.
Graph shows the percentage of Tregs in PBMCs. Bars represent
mean and SD for all the patients, p values were calculated with
Student’s paired t test, significant values are displayed. B. Graph
shows FoxP3 expression in PBMCs from patients at baseline and
after treatment. The FoxP3 expression was corrected for expression
of the housekeeping gene b actin. Bars represent mean and SD for
all the patients, p values were calculated with Student’s paired t
test, significant values are displayed.
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28 days after the last infusion (Figure 5A), whereas it has
no effect on serum RANKL (data not shown). In vitro
PBMC stimulation with iloprost confirmed this in vivo
effect (Figure 5B). These data agree with recent studies
[34-36] in which RANKL increased following stimulus
with PGE2. Iloprost increases serum IL-2.
IL-2 is a cytokine deeply involved in the control of T
cell development and function [25], and controls Treg
suppressor function [38]. Here we demonstrate that
iloprost increases IL-2 levels of about 15% after 5 days
(p = 0.008) and that this increase persists after the first
course (about 40%, p = 0.007 vs baseline). To determine
whether the effects of iloprost on TGFb and RANKL
production are mediated by IL-2, we incubated PBMCs
from buffy coats with IL-2 and found that it had no
effect on these cytokines (data not shown).
Iloprost does not affect IFNg levels
IFNg stimulates the production of pro-inflammatory
cytokines such as TNFa by macrophages [26]. It has a
pleiotropic immune function [27], and may be involved
in controlling T cell homeostasis [41, 42]. Iloprost does
not affect serum and supernatant IFNg (data not shown)
in keeping with its lack of any effect on monocyte TNF
production.
Discussion
Prostaglandin I2 is a metabolite of arachidonic acid that
has been shown to have anti-inflammatory functions
[21,28,29], however, the cellular and molecular mechan-
isms of PGI2-mediated anti-inflammatory effects remain
to be determined. Here we evaluated the effect of ilo-
prost, a PGI2 analogue, widely used in the treatment of
SSc, on T cells sub-populations and on pro-inflamma-
tory cytokines.
This study shows that infusion of iloprost, according to
the standard protocol to treat Raynaud’s phenomenon in
SSc patients, reduces T cells in the peripheral blood,
especially TNF a producing T cells, according to pre-
vious in vitro [17-19] and in vivo [21] studies. The
mechanism underling this effect was shown by Jorres et
al. [19] that found that iloprost reduces TNF a transcrip-
tional activity and decreases TNF a mRNA stability in
human peripheral blood mononuclear leukocytes stimu-
lated with LPS; Our study is the first evaluation of the
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Figure 4 Iloprost treatment increases TGF b production from
PBMCs after stimulus with PHA. TGF b was measured in the
culture supernatants of PBMCs from SSc patients treated with
iloprost at baseline and after treatment (5 days of daily treatment,
28 days after the last infusion), cultures were stimulated or not with
PHA which predominantly stimulates T cells. A. Graph shows the
level of TGF b supernatants 24 hrs after stimulus with PHA (dotted
line) or without (continuous line). Symbols represent mean and SD,
for all the patients, p values were calculated with the Wilcoxon test,
significant values are displayed. B. In vitro challenge of PBMCs
culture with iloprost for 15 and 120 min, after 24 hrs of PHA or
without further stimulus. Graph shows the TGF b in PBMCs, TGF b
expression was corrected for expression of the housekeeping gene
b actin. Bars represent mean and SD of five independent
experiments.
0 5
0
1
2
3
25 28
Time
(days)
Iloprost
infusion RANKL with PHA
RANKL without PHA
pg
/m
L
0.018 0.04
A
B
??????
??????
?????? ??????????????
?????????????????
Basal Iloprost
15'
Iloprost
120'
Co
py
 
N.
?? ??R
AN
KL
/ ??
??
???
?
???
???
??
???
???
??
???
???
??
Figure 5 Iloprost treatment increases RANKL production from
PBMCs. RANKL was measured in the culture supernatants of PBMCs
from SSc patients treated with iloprost at baseline and after
treatment (5 days of daily treatment, 28 days after the last infusion),
cultures were stimulated or not with PHA which predominantly
stimulates T cells. A. Graph shows the level of RANKL supernatants
24 hrs after stimulus with PHA (dotted line) or without (continuous
line). Symbols represent mean and SD, for all the patients, p values
were calculated with by Student’s paired t test, significant values are
displayed. B. In vitro challenge of PBMCs culture with iloprost for 15
and 120 min, after 24 hrs of PHA or without further stimulus. Graph
shows the RANKL in PBMCs, RANKL expression was corrected for
expression of the housekeeping gene b actin. Bars represent mean
and SD of five independent experiments.
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effect of iloprost on TNF a production and T cell subsets
in SSc. Our finding that iloprost acts on T cells only and
not on monocytes is in contrast with Di Renzo et al.’s
observation of a reduction of both monocytes and T cells
[21]. This discrepancy may be attributable to the fact that
they infused iloprost for 16 h/day for 7 days as required
for critical limb ischemia. Our data show that iloprost
reduces both the total amount of TNF a positive T cells
and their ability to secrete TNF a after an antigenic sti-
mulus. The role of TNF a in autoimmune diseases is well
known, and it is currently a target for monoclonal anti-
body in diseases such as rheumatoid arthritis [30]. Its
reduction by iloprost may thus be an important plus in
the evaluation of therapeutic options.
Our study demonstrates a decrease in Treg after 5
days of iloprost infusion in vivo, associated with
enhancement of their ability to produce TGF b1 in
response to immune stimulation. This effect could be
due to a generic immunomodulation by iloprost through
a systemic increase in IL-2 production, as it is well
known that this cytokine is deeply involved in the con-
trol of T cell development and function [25], and it con-
trols Treg suppressor function [38]. Our study
demonstrates that iloprost consistently increases serum
IL-2 and that this increase persists 28 days after the last
infusion. Here we show that IL 2 effect on TGF b1 pro-
duction is not direct, but may be mediated trough other
cell types in vivo. Recently a role for dendritic cells in
the mediation of iloprost anti-inflammatory activity has
been postulated [31,32]
The role of TFG b in determining the suppressor abil-
ity of Tregs is currently under debate [33], TGF b is
crucial in determining the ability of Tregs to convert
Foxp3- T cells into Foxp3+ T cells by a mechanism of
infectious tolerance [34]. Recent data suggest an impor-
tant role for Treg cells in the pathogenesis of autoim-
mune diseases [35], and it has been suggested that their
number is increased, whereas their function is impaired,
in SSc [10,30]. It may thus be supposed that the reduc-
tion in Treg number coupled with the increase in their
TGF b production may be critical for SSc therapy.
We measured the levels of RANKL in serum and in
supernatants because this molecule is important in
inflammation and in the control of immune function
[24] and expected they would be reduced after iloprost
similarly to the reduction in TNF. After iloprost instead
we found an increase in RANKL levels both as protein
and as gene copies number. This could be interpreted as
a class effect of prostaglandins, since recent studies
[34-36] have demonstrated an increase in RANKL in
cells after incubation with PGE2; moreover Conaway
and colleagues demonstrated that both PGE2 and PGI2
were able to enhance osteoclast activity that is mainly
under RANKL control [36]. However the RANKL
increase is not due to IL-2 increase as demonstrated by
the lack of IL-2 effect on in vitro PBMCs.
Our data demonstrated that iloprost does not influ-
ence IFN g production. This cytokine is particularly
involved in the inflammatory reaction of monocytes/
macrophages and induces their TNF a secretion [26];
hence the lack of effect of iloprost on IFN is in line with
the absence of its effect on monocyte TNF a
production.
Conclusions
This study suggests that iloprost has specific anti-
inflammatory and immunomodulating effects: it reduces
TNF a production by T cells without influence on TNF
a monocyte production; it reduces the Tregs number,
but ameliorates their function probably trough an
increase in IL-2 and directly increases RANKL. Hence
the therapeutic use of iloprost in SSc patients may be
useful not only as vasodilator and antifibrotic, but also
as immunomodulator agent.
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